Core Viewpoint - The company, Pruis, established in 2013 and listed in 2022, is a leading SMO enterprise in China, specializing in technology development and consulting in the pharmaceutical sector, with a strong project management and quality control capability [1] Financial Performance - In Q3 2025, Pruis achieved a revenue of 609 million yuan, ranking 14th in the industry, significantly lower than the top competitor WuXi AppTec's 32.857 billion yuan and second-place Kanglong Chemical's 10.086 billion yuan [2] - The net profit for the same period was 87.3815 million yuan, also ranking 14th, and below the industry average of 58.5 million yuan [2] Financial Ratios - As of Q3 2025, Pruis had a debt-to-asset ratio of 16.69%, lower than the industry average of 22.79%, indicating good solvency [3] - The gross profit margin was 25.58%, which, while improved from 24.52% year-on-year, remains below the industry average of 37.70% [3] Executive Compensation - The chairman, Lai Chunbao, received a salary of 496,500 yuan in 2024, a decrease from 513,000 yuan in 2023 [4] - The general manager, Yang Hongwei, earned 1.6174 million yuan in 2024, down from 1.6387 million yuan in 2023 [4] Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 0.20% to 8,588, while the average number of shares held per shareholder decreased by 0.20% to 8,770.25 [5] - Notable changes among the top ten shareholders include the entry of Noan Pioneer Mixed A as the fifth-largest shareholder and a significant reduction in holdings by Tianhong Medical Health A [5] Business Outlook - According to Changcheng Guorui Securities, Pruis's performance in the first half of 2025 showed improvement, with new orders growing rapidly, including a 40.12% year-on-year increase in new contracts totaling 600 million yuan [5] - The company is expected to see revenue growth, with projected net profits of 121 million yuan, 131 million yuan, and 141 million yuan for 2025 to 2027, respectively [5] - Xinda Securities noted significant improvements in Q2 2025, with a total of 4,157 employees and nearly 4,000 in business roles, serving over 960 clinical trial institutions across more than 200 cities [6] - The company has established a comprehensive quality control system with over 280 SOP documents, maintaining a strong reputation in project execution [6]

Core Insights - The company reported a total revenue of 609 million yuan for Q3 2025, ranking 25th among disclosed peers [1] - The net profit attributable to shareholders was 87.38 million yuan, with a net cash inflow from operating activities of 15.24 million yuan, ranking 31st among peers [1] Financial Metrics - The latest debt-to-asset ratio is 16.69% [3] - The gross profit margin stands at 25.58%, ranking 36th among disclosed peers [3] - The return on equity (ROE) is 6.98% [3] - The diluted earnings per share (EPS) is 1.11 yuan [3] - The total asset turnover ratio is 0.42 times, a decrease of 0.02 times compared to the same period last year, reflecting a year-on-year decline of 3.93% [3] Shareholder Structure - The number of shareholders is 8,588, with the top ten shareholders holding a total of 44.49 million shares, accounting for 56.31% of the total share capital [3] - The top ten shareholders and their respective holdings are as follows: 1. Shihezi Xitai Equity Investment Partnership (Limited Partnership) - 18.71% 2. Shihezi Ruixin Equity Investment Partnership (Limited Partnership) - 8.10% 3. Shihezi Ruizesheng Equity Investment Co., Ltd. - 7.40% 4. Shanghai Guanyu Investment Development Co., Ltd. - 6.93% 5. Lai Chunbao - 6.17% 6. Industrial and Commercial Bank of China - 4.17% 7. Li Weike - 1.33% 8. China Merchants Securities - 1.22% 9. Zhang Jing - 1.16% 10. China Resources Shen Guotou Trust - 1.15% [3]

Core Insights - The company reported a revenue of 609 million yuan for the first three quarters of 2025, representing a year-on-year increase of 2.59% [1] - Net profit reached 87.38 million yuan, showing a year-on-year growth of 20.92% [1] - The company attributed its performance to ongoing refined operational management measures [1] Company Overview - The company is a data-driven clinical research service provider, focusing on the management of clinical trial site organizations (SMO) [1] - It has served over 960 clinical trial institutions and has the capability to cover more than 1,300 institutions across over 200 cities in China [2] - As of the reporting period, the company had undertaken over 4,200 international and domestic SMO projects, with 2,538 projects currently in execution [2] Market Demand and Performance - The company noted a positive recovery in industry and client demand, with a significant increase in inquiry volume and new contracts [1] - The new signed contracts (excluding tax) amounted to 600 million yuan, reflecting a year-on-year increase of 40.12% [2] - The company’s backlog of contracts (excluding tax) stood at 1.998 billion yuan, up 9.45% year-on-year as of June 2025 [2] Industry Landscape - The SMO industry in China is entering a new development phase, with leading SMO companies expanding their client resources, professional talent, and research institution coverage [3] - There is an increasing concentration in the industry as smaller SMO companies begin to exit the market, benefiting larger firms with stronger technical barriers and brand influence [3]

Core Insights - The company reported a revenue of 609 million yuan for the first three quarters of 2025, representing a year-on-year growth of 2.59% [1] - The net profit attributable to shareholders of the listed company was 87.38 million yuan, showing a year-on-year increase of 20.92% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 69.67 million yuan, reflecting a year-on-year growth of 11.48% [1] - The basic earnings per share were 1.11 yuan [1]

Core Viewpoint - The company reported a modest increase in revenue and a significant rise in net profit for the third quarter, indicating a positive financial performance despite a challenging market environment [1] Financial Performance - The company's operating revenue for the first three quarters reached 609 million yuan, representing a year-on-year growth of 2.59% [1] - The net profit attributable to shareholders of the listed company was 87.38 million yuan, showing a year-on-year increase of 20.92% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 69.67 million yuan, reflecting a year-on-year growth of 11.48% [1]

Core Viewpoint - The company reported a modest increase in revenue and a significant rise in net profit for the third quarter, indicating a positive financial performance despite a challenging market environment [1] Financial Performance - The company's operating revenue for the first three quarters reached 609 million yuan, representing a year-on-year growth of 2.59% [1] - The net profit attributable to shareholders for the same period was 87.38 million yuan, showing a year-on-year increase of 20.92% [1] - The net profit after deducting non-recurring gains and losses was 69.67 million yuan, reflecting a year-on-year growth of 11.48% [1]

二、董事会会议审议情况 经与会董事认真审议，一致同意通过如下决议： （一）审议通过《关于公司<2025 年第三季度报告>的议案》 经审议，董事会认为：公司《2025 年第三季度报告》的编制程序符合法律、 行政法规和中国证券监督管理委员会、深圳证券交易所的相关法律法规、规范性 文件的规定，报告内容真实、准确、完整地反映了公司的实际情况，不存在任何 虚假记载、误导性陈述或者重大遗漏。 本议案已经公司董事会审计委员会审议通过。 证券代码:301257 证券简称:普蕊斯 公告编号:2025-063 普蕊斯（上海）医药科技开发股份有限公司 第三届董事会第十六次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 普蕊斯（上海）医药科技开发股份有限公司（以下简称"公司"）第三届董事 会第十六次会议于 2025 年 10 月 28 日在公司会议室以现场会议及通讯相结合的 形式召开，本次会议通知及会议资料已于 2025 年 10 月 24 日以专人送达、电子 邮件的方式发出，会议应出席董事 9 人，实际参与会议的董事 9 人，其中董事马 林、刘 ...

证券代码：301257 证券简称：普蕊斯 公告编号：2025-064 普蕊斯（上海）医药科技开发股份有限公司 关于 2025 年前三季度利润分配方案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1、公司 2025 年前三季度利润分配方案为：以现有公司总股本 79,004,770 股为基数，向全体股东每 10 股派发现金红利 0.68 元（含税），合计派发现金股 利 5,372,324.36 元（含税），本次不进行资本公积转增股本，不送红股。 公司分别于 2025 年 10 月 24 日、10 月 28 日召开了第三届董事会审计委员 会第十四次会议、第三届董事会第四次独立董事专门会议和第三届董事会第十六 次会议，审议通过了《关于 2025 年前三季度利润分配方案的议案》，同意公司 实施 2025 年前三季度利润分配方案。本次利润分配方案在公司 2024 年年度股东 大会授权范围内，无需提交股东会审议。 二、2025 年前三季度利润分配方案基本情况 根据公司 2025 年第三季度财务报告（未经审计），公司 2025 年前三季度实 现归属于上市 ...

普蕊斯（上海）医药科技开发股份有限公司 2025 年第三季度报告 证券代码：301257 证券简称：普蕊斯 公告编号：2025-062 普蕊斯（上海）医药科技开发股份有限公司 2025 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会及董事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担 个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第三季度财务会计报告是否经过审计 □是 否 1 普蕊斯（上海）医药科技开发股份有限公司 2025 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同 | 年初至报告期末 | 年初至报告期末 | | --- | --- | --- | --- | --- | | | | 期增减 | | 比上年同期增减 | | 营业收入（元） | 218,910,71 ...

创新药概念股午后持续拉升，诺思格20cm涨停，普蕊斯、康芝药业涨超10%，泰格医药、康龙化成、 贝达药业涨幅居前。 ...